![Scott Lauder](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Profil
Scott Lauder worked as VP-Process Sciences & Clinical Manufacturing at Merrimack Pharmaceuticals, Inc. from 2013 to 2016.
He then worked as Chief Technology Officer at Gemini Therapeutics, Inc. from 2016 to 2021.
Lauder holds a doctorate degree from Northwestern University and an undergraduate degree from the University of Manitoba.
Anciens postes connus de Scott Lauder
Sociétés | Poste | Fin |
---|---|---|
GEMI THER | Directeur Technique/Scientifique/R&D | 17/09/2021 |
MERRIMACK PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/10/2016 |
Formation de Scott Lauder
University of Manitoba | Undergraduate Degree |
Northwestern University | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
Entreprise privées | 2 |
---|---|
Gemini Therapeutics, Inc.
![]() Gemini Therapeutics, Inc. BiotechnologyHealth Technology Gemini Therapeutics, Inc. is a clinical-stage precision medicine company. It is developing novel therapeutic compounds to treat genetically defined, age-related macular degeneration. The company was founded by Johanna Seddon, Paul Barlow and Andrew Herbert on March 3, 2015 and is headquartered in Cambridge, MA. | Health Technology |
Merrimack Pharmaceuticals, Inc.
![]() Merrimack Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Merrimack Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. engages in discovering, developing, and commercializing medicines consisting of novel therapeutics paired with diagnostics for the treatment of cancer. Its pipeline includes MM-131, MM-141, and MM-310. The company was founded by Anthony J. Sinskey, Gavin MacBeath, and Ulrik B. Nielsen in 1993 and is headquartered in Cambridge, MA. | Health Technology |